The Suntrust Banks Inc. Has $254,000 Stake in Repligen Co. (RGEN)

The Suntrust Banks Inc. Has $254,000 Stake in Repligen Co. (RGEN)

Other hedge funds have also bought and sold shares of the company. Gotham Asset Management LLC boosted its stake in Repligen by 135.3% in the third quarter. Gotham Asset Management LLC now owns 140,516 shares of the biotechnology company’s stock worth $4,242,000 after buying an additional 80,799 shares during the period. Russell Investments Group Ltd. acquired a new stake in Repligen during the fourth quarter worth approximately $4,773,000. Comerica Bank boosted its stake in Repligen by 5.7% in the fourth quarter. Comerica Bank now owns 35,963 shares of the biotechnology company’s stock worth $1,112,000 after buying an additional 1,951 shares during the period. State Street Corp boosted its stake in Repligen by 12.3% in the fourth quarter. State Street Corp now owns 1,059,196 shares of the biotechnology company’s stock worth $32,643,000 after buying an additional 116,068 shares during the period. Finally, Arrowpoint Asset Management LLC boosted its stake in Repligen by 33.1% in the fourth quarter. Arrowpoint Asset Management LLC now owns 150,525 shares of the biotechnology company’s stock worth $4,639,000 after buying an additional 37,443 shares during the period. Institutional investors and hedge funds own 94.35% of the company’s stock.

Suntrust Banks Inc. reduced its position in shares of Repligen Co. (NASDAQ:RGEN) by 1.5% during the first quarter, Holdings Channel reports. The firm owned 7,251 shares of the biotechnology company’s stock after selling 110 shares during the period. Suntrust Banks Inc.’s holdings in Repligen were worth $254,000 at the end of the most recent reporting period.

Shares of Repligen Co. (RGEN) opened at 39.98 on Monday. The stock has a market capitalization of $1.36 billion, a PE ratio of 105.49 and a beta of 1.58. Repligen Co. has a 12 month low of $21.11 and a 12 month high of $40.31. The company’s 50 day moving average price is $37.68 and its 200 day moving average price is $33.49.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Thursday, May 4th. The biotechnology company reported $0.15 EPS for the quarter, beating the consensus estimate of $0.13 by $0.02. The business had revenue of $30.59 million during the quarter, compared to analysts’ expectations of $29.28 million. Repligen had a return on equity of 10.16% and a net margin of 6.89%. The company’s quarterly revenue was up 21.9% compared to the same quarter last year. During the same period last year, the firm earned $0.12 EPS. Equities analysts anticipate that Repligen Co. will post $0.56 earnings per share for the current fiscal year.

RGEN has been the subject of a number of recent analyst reports. Zacks Investment Research cut Repligen from a “hold” rating to a “sell” rating in a research report on Friday, February 17th. First Analysis restated an “equal weight” rating and issued a $40.00 price objective on shares of Repligen in a research report on Friday, April 21st.

In related news, Director Thomas F. Ryan, Jr. sold 4,000 shares of Repligen stock in a transaction on Monday, March 20th. The stock was sold at an average price of $34.83, for a total transaction of $139,320.00. Following the completion of the transaction, the director now directly owns 12,594 shares of the company’s stock, valued at $438,649.02. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CFO Jon Snodgres sold 1,909 shares of Repligen stock in a transaction on Friday, March 17th. The stock was sold at an average price of $34.91, for a total value of $66,643.19. Following the transaction, the chief financial officer now directly owns 23,789 shares of the company’s stock, valued at $830,473.99. The disclosure for this sale can be found here. Insiders sold a total of 20,646 shares of company stock valued at $714,898 over the last three months. Insiders own 2.30% of the company’s stock. About Repligen

Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:RGEN”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Co. (NASDAQ:RGEN). Receive News & Ratings for Repligen Co. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Repligen Co. and related companies with MarketBeat.com’s FREE daily email newsletter.

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Co. (NASDAQ:RGEN).

Related posts

Leave a Comment